![](https://cdn.benzinga.com/files/images/story/2024/07/23/bz-pharma-briefs.jpeg?width=1200&height=800&fit=crop)
Cancer-Focused Cellectar Biosciences Stock Trades Lower Despite Meeting Goal In Blood Cancer Study
Cellectar Biosciences Inc. CLRB stock is trading lower Tuesday after the company shared results from its CLOVER WaM pivotal study. The study evaluated iopofosine I 131, a targeted radiotherapeutic candidate, for relapsed/refractory Waldenstrom’s …